Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioSante Bio-E-Gel Phase III data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

BioSante plans an NDA submission for its transdermal estradiol gel Bio-E-Gel "as soon as possible" following positive results from a Phase III trial in menopausal women. The 12-week, 484-patient study looked at three dose levels. Beginning at week five, highly significant decreases in the number (p<0.001) and severity (p<0.01) of hot flashes compared to placebo were observed with the lowest study dose. "We believe the low dose…will be an attractive alternative to currently marketed estrogen therapies," BioSante says. The company is aiming at the market created largely by Solvay's EstroGel. BioSante also hopes to tap into the female sexual dysfunction market with its testosterone gel LibiGel. A Phase III study in FSD is slated to begin by year-end (1Pharmaceutical Approvals Monthly April 2005, p. 5)...

You may also be interested in...

Palatin ED Alternative PT-141 May Lack Nitrate Interaction; Phase III In 2006

Rejection Rate Soars In Q4 For EU Fast-Track Requests

October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.

Biden Regulatory Freeze May Pause SUNSET Rule

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts